MannKind Corporation (NASDAQ: MNKD) is having an incredibly strong time in the pre-market hours today, and for good reason. The company is setting up to report its earnings after the closing bell today, and investors are excited. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (8:41), MNKD is trading at $1.30 per share after a gain of $0.18 per share (16.07%) thus far today.
MNKD Reports Earnings Today
As mentioned above, MannKind is scheduled to report its earnings after hours today, and that’s causing quite a bit of positive movement in the stock at the moment. During the quarter, it is expected that MNKD will generate a loss of $0.09 per share. This is a steep decline on a year-over-year basis. In the same quarter last year, the company generated a loss of $0.03 per share. However, earnings may not be the big story here.
Investors Are Excited For The Future
While we know that earnings aren’t set up to be great this quarter, it’s not necessarily the earnings that investors will be focused on when it comes to the report. At the end of the day, MNKD investors are looking for guidance as to what they can expect in the future, and while I didn’t think I’d be saying this any time soon, the future may be very, very bright.
The first thing that I’m expecting that we’ll hear about on the sales front is the ongoing work on a partnership with One Drop | Chrome. One Drop is a company that works on diabetes monitoring systems and has a state of the art system that is considered to be the best in the business. The company has signed several agreements, partnering with insurance companies, Amazon, and, you called it, they’ve got an intent to work with MannKind.
In fact, One Drop recently entered into a memorandum of understanding to enter into a collaborative agreement with MNKD. When the agreement is signed, Afrezza will be added to the company’s app and promoted through One Drop. That’s incredible news considering the fact that on Monday, One Drop | Chrome officially got added to the Amazon Prime list of products! At the end of the day, this means that Afrezza will see more awareness, likely leading to more sales in the future.
Another thing that investors are likely waiting for here is an update with regard to the commercialization of Afrezza. Of course, the One Drop news update is likely to be part of that, but what else is the company doing to sell the treatment? Ultimately, we’re likely to learn more when earnings are released. Nonetheless, investors seem very excited about the prospect of growth.
Stop wasting your time! Find winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will be keeping a close eye on MNKD. In particular, we’re interested in learning more details about the One Drop collaboration as well as other efforts by the company on the commercialization of Afrezza. We’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!